Most early-stage founders think about R&D spending in one direction: money out. You fund the research, develop the technology, test it, refine it, protect the intellectual property and keep investing until, hopefully, you have something you can bring to market.
That makes sense if you think of R&D strictly as the process required to create a product. But after working with licensing opportunities for decades, I’ve learned that can be an expensive way to look at intellectual property. While you’re developing the product, you may also be creating technical data, formulations, processes, methods, testing results, specialized know-how, trade secrets and patentable inventions. Collectively, those can become commercially valuable assets long before you’ve sold your first product.
And in some cases, they may be licensable before the product itself is ready for market.
When R&D Starts Becoming an Asset
This is particularly important for R&D-intensive startups in medical technology, biotechnology, food technology, materials, specialty formulations and other technical industries. A company may spend years developing something without recognizing that it’s accumulating multiple layers of intellectual property and commercial value along the way.
The mistake is assuming none of that value matters until the finished product generates revenue. I’ve sat across the table from founders who had spent considerable time and money developing genuinely valuable technology, but when I asked what they actually had available to license, they pointed to the patent or prototype. They weren’t thinking about the research, technical knowledge, processes, data and know-how surrounding it.
That’s often where some of the most interesting licensing value is hiding.
Licensing Doesn’t Always Start With a Finished Product
Another assumption I hear frequently is that a technology isn’t ready to be considered for licensing until it has traction. Founders think they need revenue, customers, a production-ready product or substantial market validation before another company will be interested.
Sometimes that’s true, but licensing readiness and product readiness aren’t the same thing. A potential licensee may not be asking, “Can we sell this finished product tomorrow?” They may be asking whether your technology gives them an advantage that would be faster, less expensive or less risky than developing the same capability themselves.
That’s a very different conversation.
An established company may already have manufacturing, distribution, regulatory expertise, customers and a sales organization. What it may not have is your particular technology, formulation, process, data or specialized know-how. Licensing can give that company access to something valuable without forcing it to start the R&D process from zero.
Strong Science Can Open the Door — But It Isn’t Enough
I worked with a cognitive-health and supplement opportunity that illustrates this well. There was substantial science behind it, including published research and intellectual property, and enough commercial potential to generate discussions with supplement executives, scientists, formulation specialists and other industry participants. NDAs were signed and conversations advanced.
The important point is that companies were interested in the underlying research and opportunity. They weren’t waiting for someone to build a complete consumer-products company first. But the experience also demonstrated something equally important: strong science didn’t automatically make the opportunity ready to license.
As discussions moved forward, questions involving process ownership, communication, stakeholder alignment and the overall commercialization structure became increasingly important. The science opened doors, but it couldn’t carry the entire licensing process. That’s something I’ve seen repeatedly over the years: scientific or technical credibility can create interest, but commercialization readiness determines whether that interest has somewhere to go.
Companies License Business Opportunities
This is where the distinction becomes important. Your research may become a licensable asset, but that doesn’t mean a company wants to license a stack of laboratory notebooks, technical reports or patent documents.
The research has to be translated into a business opportunity.
A prospective licensing partner needs to understand what problem you’ve solved, why that problem matters commercially, what you’ve proven, what remains to be done and how the technology fits into something the company already wants to accomplish. That’s a very different presentation from simply saying, “Here’s what we invented.”
The better conversation is: “Here’s what we’ve developed, here’s the evidence supporting it, here’s the commercial problem it addresses, and here’s how your company could use it.”
That shift—from explaining the invention to presenting the opportunity—is where commercialization really starts.
What a Licensee Is Actually Looking For
When a company evaluates early-stage technology, it usually isn’t evaluating the technology in isolation. It’s trying to understand what access to that technology could do for the business.
Could it shorten development time, solve an existing technical problem, improve a current product, open a new application or market, reduce development risk, or provide a competitive advantage? Could the company acquire through licensing something that would take several years and considerably more money to develop internally?
Those are business questions, not patent questions.
And that’s why simply having a patent or prototype isn’t enough. A licensee has to see the commercial case surrounding it. If they can’t understand why your technology matters to their business, the amount of money you’ve spent developing it won’t make much difference.
Turn Your R&D Documentation Into Commercial Evidence
This is another area where founders often leave value on the table. They treat R&D documentation as something prepared for scientists, engineers, patent attorneys, regulators or accountants. Those are all legitimate reasons to document the work, but good R&D documentation can also become part of the evidence supporting a licensing opportunity.
I’ve reviewed projects where valuable information was scattered across laboratory notebooks, testing files, presentations, internal reports and email conversations. The knowledge existed, but the commercial story didn’t.
That’s a problem when a licensing partner starts evaluating the opportunity. The person you’re talking with may have to take your technology back to engineering, regulatory, marketing, finance or senior management and explain why the company should spend more time evaluating it. They need evidence they can defend internally. “Trust us, it works” doesn’t travel very far inside a corporation, while documented testing, technical milestones, reproducible results and clearly defined intellectual property do.
Start Packaging the Research Around Four Questions
You don’t need a hundred-page commercialization report to begin thinking about your R&D as a licensable asset. Start by asking yourself four practical questions: What commercial problem does this research solve? What have we actually proven? What intellectual property, data and know-how have we created? And what would a licensing partner still have to do to turn what we have today into a commercial product or application?
Those questions force you to look beyond the invention itself. They help separate what you’ve demonstrated from what you’re still assuming, and they begin connecting your technical work to an actual business opportunity.
Once you can answer them clearly, you’re no longer simply describing an R&D project. You’re beginning to define a commercialization opportunity that another company can evaluate.
Don’t Wait Until the R&D Is Finished
There’s another reason I think founders should start this process earlier: it can change how you spend your next R&D dollar.
If licensing is a possible commercialization pathway, you can start asking whether each new development milestone will make the technology more attractive to a prospective partner. That may influence which tests you prioritize, what data you collect, which applications you validate and even which parts of the technology you protect.
Instead of developing everything in isolation and asking at the end, “Who might license this?”, you’re developing with the eventual licensing decision in mind. That’s a much more strategic use of R&D and can help prevent the common mistake of spending heavily on features or capabilities that matter to the inventor but don’t materially increase the value of the opportunity to a licensee.
One R&D Investment Can Create Several Forms of Value
There can also be financial benefits associated with R&D spending. Depending on the company, jurisdiction and nature of the work, qualifying research expenses may be eligible for R&D-related tax incentives, something that should be discussed with a qualified tax professional.
But I think the larger point is more interesting. The same R&D investment may support your future product, strengthen your intellectual property position, create proprietary know-how, generate technical validation, increase strategic value and potentially create an asset another company would rather license than develop itself.
That’s very different from viewing R&D simply as money you have to spend before commercialization begins.
Take Another Look at What You’ve Already Built
If you’re running an R&D-intensive startup, take another look at what you’ve created so far. Don’t just look at the finished product or the patent. Look at the research, testing, data, methods, processes, know-how and intellectual property that have accumulated during development.
Then ask yourself a different question: Could what we’ve already developed solve a commercially important problem for a company that already has the resources to bring it to market?
You may discover that the most important commercialization asset you’re building isn’t simply the eventual product. It may be the body of intellectual property, technical knowledge and know-how being created while you’re developing it—and that asset may be ready for a licensing conversation sooner than you think.
Explore the Licensing Potential of Your R&D
If you’ve invested significantly in R&D and aren’t sure whether you’ve created a licensable asset, it may be worth finding out before simply investing more money in development. Licensing Consulting Group helps innovators and companies look at their intellectual property from a commercialization perspective, identify potential licensing opportunities and determine what needs to be developed or positioned before approaching prospective partners.
Schedule a Licensing Strategy Call and let’s take a practical look at what you’ve built, where the commercial value may be, and whether licensing should be part of your commercialization strategy.
You can also subscribe to the Licensing Consulting Group newsletter for more practical insights, case studies and strategies for turning intellectual property into commercial opportunities.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.